Navigation Links
ProMetic provides business update - Over $35 million worth of business secured in January

- Shipment of prion capture resin to MacoPharma in Q1 2008; - MacoPharma increased its forecast for P-Capt(R) filters sale in 2008; - Use of affinity prion adsorbent for plasma-derived products to generate

in excess of $25 M over the next 5 years

- $4 M in 2008; - 10th product approved by the FDA and or the EMEA, contributing to revenue


MONTREAL, Feb. 6 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today provided an update on its business activities.

"Key milestones were achieved in January, a prelude to the announced growth for 2008 and beyond," stated Pierre Laurin, ProMetic's President and Chief Executive Officer. "With our Protein Technologies Business expected to be EBITDA positive this year, and to generate an EBITDA in excess of $15 M in 2009, as well as a partnering of PBI-1402 in 2008, we clearly are on track to deliver value to our shareholders," added Mr. Laurin.

- ProMetic to ship prion capture resin in Q1 2008 for incorporation into

the P-Capt(R) filter. This is in response to MacoPharma's increased

product requirements to meet the expected sales of the P-Capt(R) filter

to Ireland and the UK in 2008. This favorably impacts ProMetic revenue

as of the first half of 2008.

- ProMetic confirmed the decision of a major European plasma fractionator

to scale-up the prion removal process. This process ensures the removal

of any abnormal prion proteins that may be present in donated plasma

and will add another level of safety to the already established

treatment protocols.

- Expected completion of the scale-up phase is June 2008, providing

ProMetic approximately $1 M;

- Including Kedrion, this will signify two major European plasma

fractionators using the prion reduction resin at scale,

representing annual recurring revenue of $5 M. The initial five-

year supply agreement is in final stage of negotiation with

commercial quantities of resin supply commencing as soon as mid-

2008, following regulatory approval of the product.

- The Food and Drug Administration ("FDA") has granted approval to

Zymogenetics, Inc. for the commercial sale of Recothrom(R) a

recombinant thrombin product which is manufactured using a synthetic-

ligand affinity adsorbent supplied by ProMetic. This is one of ten

licenced products that have now been approved for sale by the FDA

and/or the European Medicines Agency ("EMEA") which uses ProMetic's

purification technology as part of their manufacture or function.

- Improved sensitivity by 80-fold of existing diagnostic devices was

achieved by pre-treating the samples with PRDT's enhanced concentration

technology. The results showed an added level of sensitivity to the BSE

detection process, thereby reducing the risk of "false outcomes" with

existing tests. This could allow for the detection of infectious prions

at an earlier phase in the development of the disease, thus improving

the safety of the food industry for the countries testing for BSE.

A more comprehensive update for PBI-1402 will be provided shortly as the Company is pursuing its clinical development and as partnership discussions are accelerating.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
2. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
3. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
6. YM BioSciences provides update on AeroLEF(TM) clinical development program
7. ViroPharma Provides 2008 Outlook
8. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
9. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
10. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
11. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):